MMP2 and prostate carcinoma: Together, these data suggest that, similar to genetic knockdown, pharmacological inhibition of PBK strongly reduces two hallmarks of cancer in prostate cancer cells, namely, invasive ability, via down-regulation of β-catenin-mediated production of MMP-2 and -9, and proliferation.